Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Non-Current Assets of $21.6 million for Q2 2026, down 65.88% year-over-year from $63.3 million in Q2 2025, and up 9.18% quarter-over-quarter from $19.8 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Non-Current Assets for 17 consecutive years, with $21.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 65.88% year-over-year to $21.6 million; the TTM figure through Jun 2026 stood at $93.8 million (down 72.12% YoY), while the FY2025 annual figure was $20.9 million, down 76.77% from the prior year.
- Non-Current Assets improved to $21.6 million in Q2 2026 per AMRN's latest filing, from $19.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $254.1 million in Q2 2022 and bottomed at $19.8 million in Q1 2026.
- Historically, Non-Current Assets has averaged $114.6 million across 5 years, with a median of $101.2 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 418.6% — and 2025, when it sank 76.77%.
- Amarin Corp Plc\Uk's Non-Current Assets stood at $197.1 million in 2022, then sank by 45.86% to $106.7 million in 2023, then slipped by 15.7% to $90.0 million in 2024, then tumbled by 76.77% to $20.9 million in 2025, then gained by 3.38% to $21.6 million in 2026.
- Business Quant data shows AMRN's Non-Current Assets at $21.6 million in Q2 2026, $19.8 million in Q1 2026, and $20.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 21.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60 Mn |
| Mar 31, 2026 | 19.78 Mn |
| Dec 31, 2025 | 20.89 Mn |
| Sep 30, 2025 | 31.48 Mn |
| Jun 30, 2025 | 63.31 Mn |
| Mar 31, 2025 | 82.60 Mn |
| Dec 31, 2024 | 89.95 Mn |
| Sep 30, 2024 | 100.40 Mn |
| Jun 30, 2024 | 98.06 Mn |
| Mar 31, 2024 | 102.08 Mn |
| Dec 31, 2023 | 106.70 Mn |
| Sep 30, 2023 | 121.52 Mn |
| Jun 30, 2023 | 153.52 Mn |
| Mar 31, 2023 | 176.38 Mn |
| Dec 31, 2022 | 197.08 Mn |
| Sep 30, 2022 | 221.78 Mn |
| Jun 30, 2022 | 254.11 Mn |
| Mar 31, 2022 | 201.09 Mn |
| Dec 31, 2021 | 189.34 Mn |
| Sep 30, 2021 | 72.77 Mn |